Literature DB >> 351429

Toward drugs derived from cannabis.

R Mechoulam, E A Carlini.   

Abstract

Recent work aimed at the introduction of natural and synthetic cannabinoids as drugs is reviewed. Delta1-Tetrahydrocannabinol (delta1-THC) is mainly investigated as a potential drug against glaucoma and asthma, and as an antiemetic agent in cancer chemotherapy. Cannabidiol is being tried in the clinic against epilepsy and as a hypnotic. Numerous synthetic cannabinoids are currently being investigated as analgetics and as sedative-relaxants.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 351429     DOI： 10.1007/bf00450585

Source DB:  PubMed          Journal:  Naturwissenschaften        ISSN： 0028-1042


  30 in total

1.  Marihuana, tetrahydrocannabinol and T-cell function.

Authors:  B H Petersen; J Graham; L Lemberger
Journal:  Life Sci       Date:  1976-08-01       Impact factor: 5.037

Review 2.  Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta9-tetrahydrocannabinol.

Authors:  L E Hollister
Journal:  Pharmacology       Date:  1974       Impact factor: 2.547

3.  Effects of delta-9-tetrahydrocannabinol on cyclopropane MAC in the rat.

Authors:  T S Vitez; W L Way; R D Miller; E I Eger
Journal:  Anesthesiology       Date:  1973-06       Impact factor: 7.892

4.  Antipyretic, analgesic and anti-inflammatory effects of delta 9-tetrahydrocannabinol in the rat.

Authors:  D S Kosersky; W L Dewey; L S Harris
Journal:  Eur J Pharmacol       Date:  1973-10       Impact factor: 4.432

5.  Clinical pharmacology of nabilone, a cannabinol derivative.

Authors:  L Lemberger; H Rowe
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

6.  Antitussive activity of some naturally occurring cannabinoids in anesthetized cats.

Authors:  R Gordon; R J Gordon; D Sofia
Journal:  Eur J Pharmacol       Date:  1976-02       Impact factor: 4.432

7.  Prolonged delta-9-tetrahydrocannabinol ingestion. Effects of sympathomimetic amines and autonomic blockades.

Authors:  N L Benowitz; R T Jones
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

8.  Effect of oral administration of delta-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects.

Authors:  R T Abboud; H D Sanders
Journal:  Chest       Date:  1976-10       Impact factor: 9.410

9.  Anti-edema and analgesic properties of delta9-tetrahydrocannabinol (THC).

Authors:  R D Sofia; S D Nalepa; J J Harakal; H B Vassar
Journal:  J Pharmacol Exp Ther       Date:  1973-09       Impact factor: 4.030

10.  A potent antinociceptive cannabinoid which lacks opiate substitution properties in monkeys.

Authors:  B R Martin; W L Dewey; M D Aceto; M D Adams; J T Earnhardt; J M Carney
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1977-01
View more
  32 in total

1.  Marijuana use and the risk of new onset seizures.

Authors:  J C Brust; S K Ng; A W Hauser; M Susser
Journal:  Trans Am Clin Climatol Assoc       Date:  1992

Review 2.  Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Authors:  Orrin Devinsky; Maria Roberta Cilio; Helen Cross; Javier Fernandez-Ruiz; Jacqueline French; Charlotte Hill; Russell Katz; Vincenzo Di Marzo; Didier Jutras-Aswad; William George Notcutt; Jose Martinez-Orgado; Philip J Robson; Brian G Rohrback; Elizabeth Thiele; Benjamin Whalley; Daniel Friedman
Journal:  Epilepsia       Date:  2014-05-22       Impact factor: 5.864

3.  Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States.

Authors:  Mahmoud A ElSohly; Zlatko Mehmedic; Susan Foster; Chandrani Gon; Suman Chandra; James C Church
Journal:  Biol Psychiatry       Date:  2016-01-19       Impact factor: 13.382

Review 4.  Cannabinoids in Pediatrics.

Authors:  Christopher T Campbell; Marjorie Shaw Phillips; Kalen Manasco
Journal:  J Pediatr Pharmacol Ther       Date:  2017 May-Jun

Review 5.  Marijuana Legalization: Impact on Physicians and Public Health.

Authors:  Samuel T Wilkinson; Stephanie Yarnell; Rajiv Radhakrishnan; Samuel A Ball; Deepak Cyril D'Souza
Journal:  Annu Rev Med       Date:  2015-10-19       Impact factor: 13.739

6.  Cannabidiol: promise and pitfalls.

Authors:  Timothy E Welty; Adrienne Luebke; Barry E Gidal
Journal:  Epilepsy Curr       Date:  2014-09       Impact factor: 7.500

Review 7.  Plant-Derived and Endogenous Cannabinoids in Epilepsy.

Authors:  Alberto Verrotti; Miriam Castagnino; Mauro Maccarrone; Filomena Fezza
Journal:  Clin Drug Investig       Date:  2016-05       Impact factor: 2.859

8.  Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.

Authors:  Victoria Golub; D Samba Reddy
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 9.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

10.  Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Authors:  Brenda E Porter; Catherine Jacobson
Journal:  Epilepsy Behav       Date:  2013-12       Impact factor: 2.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.